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ABSTRACT
The crucial role of androgen receptor (AR) in prostate
cancer development is well documented, and its
inhibition is a mainstay of prostate cancer treat-
ment. Here, we analyze the perturbations to the AR
cistrome caused by a minor groove binding molecule
that is designed to target a sequence found in a
subset of androgen response elements (ARE). We
find treatment with this pyrrole-imidazole (Py-Im)
polyamide exhibits sequence selectivity in its repres-
sion of AR binding in vivo. Differentially changed loci
are enriched for sequences resembling ARE half-
sites that match the Py-Im polyamide binding pref-
erences determined in vitro. Comparatively, permu-
tations of the ARE half-site bearing single or dou-
ble mismatches to the Py-Im polyamide binding se-
quence are not enriched. This study confirms that the
in vivo perturbation pattern caused by a sequence
specific polyamide correlates with its in vitro bind-
ing preference genome-wide in an unbiased manner.
INTRODUCTION
Transcription factors regulate cellular gene expression and
the loss of this regulatory balance can lead to a myriad of
genetic diseases including cancer. The role of androgen re-
ceptor (AR) in prostate cancer is one of the most well char-
acterized examples. Early work in 1941 by Charles Hug-
gins and Clarence Hodges showed that the progression of
prostate cancer can be controlled by androgen deprivation
through castration or hormonal therapy with estrogen (1).
Later the discovery of the first anti-androgen, cyproterone
acetate, allowed direct inhibition of androgen binding to
the AR (2). Since then, the AR has remained the primary
target for systemic therapeutics for prostate cancer patients
(3,4). In recent years, newer anti-androgens including enza-
lutamide and apalutamide have already been approved and
others are in late-stage clinical development (5–7).
Metastatic prostate cancers treated with androgen sup-
pressive therapy will ultimately progress to a disease
state termed castration-resistant prostate cancer (CRPC).
Second-line AR directed therapeutics, such as enzalu-
tamide, are often effective against CRPC, but a second dis-
ease progression is almost inevitable. Two mechanisms that
have been documented to confer resistance to second-line
AR directed therapies are mutations to the AR C-terminal
ligand-binding domain and expression of AR splice vari-
ants lacking the ligand-binding domain (8–10). Multiple
approaches have been explored to overcome these resistance
mechanisms, as reviewed recently by Jung et al. (11). These
include AR transcription activation domain inhibitors such
as EPI-506 and AR DNA-binding domain inhibitors, such
as pyrvinium pamoate (11). In addition, our lab has pre-
viously reported the use of DNA binders to allosterically
modulate the binding of AR at the protein–DNA interface
(12). We have shown this approach to be efficacious in sev-
eral prostate cancer models, including anti-androgen resis-
tant models (13,14).
Pyrrole-imidazole (Py-Im) polyamides are DNA minor
groove bindingmolecules withmodular sequence specificity
that bind to target sites with affinities comparable to DNA-
binding proteins (15,16). Minor groove sequence recogni-
tion is determined by the pairing ofN-methylimidazole (Im)
and N-methylpyrrole (Py); the target sequence of a partic-
ular polyamide is dependent on the location of the Im and
Py monomers within the hairpin structure (17). An Im/Py
pair will recognize a G•C pair in the DNA, Py/Im will rec-
ognize C•G and Py/Py will bind to either A•T or T•A (18–
20). Upon binding to the minor groove, Py-Im polyamides
cause an expansion of the minor groove and a correspond-
ing compression in the opposing major groove (21). Py-Im
polyamides have been shown to interfere with DNA depen-
dent processes such as gene expression, RNA polymerase
II elongation, DNA polymerase replication and topoiso-
merase activity (13,22–24). They have also been shown to
activate p53 and induce apoptosis without genotoxicity, and
to have antitumor activity in prostate cancer cell lines and
xenograft models (13,14,23). ARE-1 is a Py-Im polyamide
designed to target the sequence 5′-WGWWCW-3′, whereW
represents either A or T, which is found in a subset of an-
drogen response elements (ARE).
In this study, we evaluate the anti-proliferative effects of
ARE-1 in the setting of enzalutamide resistant LNCaP-95
cells, and in the context of AR signaling. We further exam-
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ine the disruption pattern to the cistrome caused by ARE-1
treatment. We find that at loci where AR binding is reduced
byARE-1 treatment, the consensus AREmotif bears closer
resemblance to the ARE-1 target sequence, whereas the na-
tive consensus motif has more sequence degeneracy.
MATERIALS AND METHODS
Cell culture
The LNCaP-95 cell line was obtained from the laboratory
of Dr. Jun Luo at Johns Hopkins School of Medicine. The
cells were received at passage 3 and maintained in phenol
red free RPMI 1640 (Gibco 11835-030) with 10% charcoal
treated fetal bovine serum (CTFBS). All experiments were
performed below passage 20, and cells were validated to
parental cell line and confirmed mycoplasma free by ATCC
following experimentation.
Cell uptake
Cell uptake was confirmed by confocal imaging. Briefly,
LNCaP-95 cells were plated in 35-mm optical dishes (Mat-
Tek) at 7.5 × 104 cells per dish and allowed to adhere for
24 h. Cells were treated with 2 M ARE-1-FITC for 16 h,
washed with phosphate buffered saline (PBS) and imaged at
the Caltech Biological Imaging Facility using a Zeiss LSM
710 inverted laser scanning confocal microscope equipped
with a 63× oil immersion lens.
Cytotoxicity assay
LNCaP-95 cells were plated at 7.5 × 103 per well in 96
well plates. Cells were allowed to adhere for 24 h, and me-
dia was then replaced with fresh media containing vehi-
cle or polyamide ARE-1. After 72 h, an equivalent volume
of CellTiter-Glo (CTG) reagent (Promega) was added to
each well. Luminescence was allowed to stabilize for 10 min
at room temperature, according to manufacturer instruc-
tions, and then measured on a FlexStation3 plate reader
(Molecular Devices). Background subtracted luminescence
of polyamide treated cells was normalized to vehicle treated
cells, and non-linear regression analysis (Prism software,
Graphpad) was performed to determine IC50 value.
Gene expression analysis by quantitative RT-PCR (qPCR)
LNCaP-95 cells were cultured for 24 h after plating in six
well plates at 7.5 × 104 cells/ml. Cells were treated with
10 M ARE-1 with 10 nM dihydrotestosterone (DHT) or
DMSO for 24 h before harvest. RNA extraction (RNEasy
columns, Qiagen), complementary DNA (cDNA) gener-
ation (ProtoScript II First Strand cDNA Synthesis Kit,
NEB), and qRT-PCR (PowerUp SYBRGreenMasterMix,
Life Technologies, ABI7300 instrument) were done follow-
ing manufacturer recommendations. Expression was nor-
malized to -glucuronidase.
Bioavailability in new formulation
All animal experiments were performed at the Califor-
nia Institute of Technology (Pasadena, CA) with prior
IACUC approval. To evaluate a new formulation for
polyamide delivery, ARE-1 was injected at 10 mg/kg in a
1% polyvinylpyrrolidone 10 (PVP), 50 mMTris, 0.9% saline
vehicle into the right flank of 6 C57BL/6J mice. Mice were
anesthetized using isoflurane and blood collected retro-
orbitally at 30min, 1, 3, 6, 12 and 24 h after injection. Blood
samples were centrifuged at 6000 rpm for 5 min to collect
the serum, which was processed as previously published and
analyzed by HPLC to determine polyamide concentration
(25). 9-aminoacridine was used as an internal standard.
Xenograft assay
Male SCID hairless outbred mice (4–6 weeks old) were ob-
tained from Charles River Laboratories. LNCaP-95 cells
(3 × 106) were injected into the flanks of the mice as a
1:1 mixture in Matrigel (BD Biosciences). Mice were mon-
itored for the appearance of tumors and calipered twice
weekly once tumors appeared. When tumors reached 100
mm3 (using 0.5*l*w*w), animals were castrated by veteri-
nary staff. Following surgery, animals were monitored daily
for 3 days, and allowed to recover for 7–10 days prior to
the start of treatment. After the recovery period, animals
were randomly assigned to treated or vehicle groups, and
injected three times per week with 2.5 mg/kg ARE-1 or ve-
hicle (1% polyvinylpyrrolide 10 (PVP), 50 mM Tris, 0.9%
saline) for 3 weeks. Tumor growth was monitored weekly
by calipers, and growth compared to starting size. Animals
were anesthetized with 2–5% isoflurane/air when necessary,
and sterile technique was used for all procedures. Animal
health was monitored daily by veterinary staff, and any an-
imals exhibiting signs of distress were euthanized by admin-
istration of isoflurane followed by carbon dioxide.
Chromatin immunoprecipitation
Genomic occupancy of full-length AR was determined by
chromatin immunoprecipitation (ChIP) with the PG21 AR
antibody (Millipore). LNCaP-95 cells were plated at 20 mil-
lion cells per plate in phenol red-free RPMI 1640 supple-
mented with 10% CTFBS and allowed to adhere for 24 h.
The cells were treated with 10MARE-1with either 10 nM
DHT or DMSO for 24 h. Crosslinking was performed with
1% formaldehyde in media for 15 min followed by quench-
ing with 0.125 M glycine. The cells were then washed with
ice-cold PBS twice and harvested. Chromatin was sheared
by sonication at−20◦C at 25% amplitude in 30 s on and 10 s
off cycles for 30 cycles. Next, 1mg of sheared chromatin was
incubated with PG21 antibody that was previously immobi-
lized on Dynabeads (Invitrogen) overnight at 4◦C. Samples
were thenwashed 5×with LiCl buffer (10mMTris, 500mM
LiCl, 1% NP-40, 1% sodium deoxycholate) and once with
TE buffer. DNA was then harvested by phenol chloroform
extraction and purified using the Monarch PCR & DNA
Cleanup kit (NEB). Quantitative polymerase chain reac-
tion (qPCR) was used to validate enrichment at the KLK3
ARE I site (5′-TGCATCCAGGGTGATCTAGT-3′ and 5′-
ACCCAGAGCTGTGGAAGG-3′) compared to a nega-
tive internal locus (5′-TAGAAGGGGGATAGGGGAAC-
3′ and 5′-CCAGAAAACTGGCTCCTTCTT-3′) prior to
submission for sequencing. Each sample was immunopre-
cipitated as three technical replicates, which were combined
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for sequencing on an Illumina HiSeq2500. Biological repli-
cates of each treatment condition were acquired. Input
DNA (not immunoprecipitated) was also extracted and pu-
rified using the same methods and submitted for sequenc-
ing.
ChIP-Seq analysis
At least 29.7 million reads were sequenced for each sam-
ple. Reads were mapped to the human genome (hg19) using
Bowtie2 v 2.2.3 and converted to BAM format with SAM-
tools (26,27). Peak calling was performed using the model-
based analysis of ChIP-Seq (MACS2) program for each
replicate (28). Peaks from each replicate of each condition
were compared using irreproducible discovery rate (IDR) to
determine a set of reproducible peaks, which was then sub-
mitted to multiple EM for motif elicitation (MEME)-ChIP
(http://meme-suite.org/tools/meme-chip) for motif analysis
(29–31). Peaks selected by IDR were converted to bigWig
format for viewing in the UCSC genome browser (http:
//genome.ucsc.edu).
Differential analysis between treatment conditions was
conducted using peak-calling prioritization (PePr) with a
P-value cutoff of 1 × 10−5, sharp peaks and intra-group
normalization (32). PePr results were used for all further
analysis. BEDtools was used for overlap analysis and peak
annotation was performed using ChIPseeker (33,34). Dif-
ferentially changed peaks were submitted to MEME-ChIP
for motif finding as above. Based on the MEME-ChIP re-
sults,Homerwas used to examine the density of specificmo-
tifs within peaks (35). Data has been deposited and can be
accessed in GEO (GSE125552).
Thermal stabilization assay
Melting temperature analysis of the DNA oligos 5′-
TTGTAGAACACGTT-3′, 5′-TTGTAGGACACGTT-
3′, 5′-TTGTGGAACACGTT-3′ and 5′-
TTGTGGGACACGTT-3′ in the presence of ARE-1
was conducted as previously described (36).
Statistical analysis
All statistical analysis was performed in GraphPad Prism.
Gene expression data were normalized to the DHT in-
duced condition and ANOVA analysis was performed on
three biological replicates using the Dunnett’s test for mul-
tiple comparisons. Statistical analysis of tumor percentage
growth between vehicle and ARE-1 treated groups (N = 11
per group) was performed using the unpaired t-test. All re-
ported P-values are two-sided.
RESULTS
Nuclear uptake and cytotoxicity
Py-Im polyamide ARE-1 has been previously shown to
exhibit antiproliferative activity toward several models of
prostate cancer including LNCaP, LNCaP-AR, VCaP and
LREX′ (14,22). We further evaluate the activity of ARE-
1 in LNCaP-95 cells, which derive their resistance from
the expression of AR splice variants (37). Nuclear local-
ization of ARE-1 (Figure 1A) was confirmed using a flu-
orescein analog, ARE-1-FITC (Supplementary Figure S1),
in LNCaP-95 cells (Figure 1B). Antiproliferative effect of
ARE-1 toward LNCaP-95 cell growth was evaluated us-
ing the CTG assay and compared against the antiandro-
gen enzalutamide and pyrvinium pamoate (pyrvinium), a
molecule that has been reported to bind to the AR DNA-
binding domain to prevent AR–DNA interactions (38).
Results from the assay show the 72 h growth inhibition
IC50s for ARE-1, enzalutamide and pyrvinium to be 20.1
M, >30 M and 44 nM, respectively. A synergistic ef-
fect was observed when a subtoxic concentration of enza-
lutamide (5 M) was combined with polyamide, and the
IC50 was reduced to 3.4 M. Changes to KLK3 gene ex-
pression was also evaluated in LNCaP-95 cells treated with
ARE-1, enzalutamide, pyrvinium, and a combination of
ARE-1 with pyrvinium or enzalutamide (Figure 1D). Af-
ter 24 h of treatment, the greatest reduction in KLK3 ex-
pression from treatment with a single agent came from
ARE-1, and combining either additional agent with ARE-
1 further reduced gene expression. Based on these cell cul-
ture results, we further evaluated the antitumor effects of
ARE-1 in LNCaP-95 xenografts using an optimized for-
mulation that increased the subcutaneous bioavailability
when compared to the previously used DMSO/saline ve-
hicle (Supplementary Figure S2A). Animals were engrafted
with LNCaP-95 cells and monitored until palpable tumors
were observed. Once tumors reached 100 mm3, the animals
were castrated, allowed to recover for ∼1 week and then
randomized before treatment (Figure 1E). The animals were
treated with either vehicle or 2.5 mg/kg ARE-1 subcuta-
neously Monday/Wednesday/Friday for 3 weeks. The ve-
hicle treated group grew ∼380%, while the ARE-1 treated
group grew 225%, for a 40% reduction in tumor size in
the polyamide treated mice (Figure 1F). Animal weight was
measured at each injection and was not adversely affected
(Supplementary Figure S2B).
Genomic perturbation of androgen receptor occupancy
The effects of Py-Im polyamide treatment on AR occu-
pancy on chromatin have previously been explored by ChIP
experiments. A related Py-Im polyamide, targeting the same
sequence as ARE-1, has previously been shown to decrease
occupancy of AR at the KLK3 promoter and enhancer in
LNCaP cells (12). In LNCaP-95 cells, a similar reduction
at the KLK3 promoter ARE I is seen after 24 h of co-
treatment with ARE-1 and 10 nM DHT (Supplementary
Figures S3A). In this study, we explored the genomic effect
ARE-1 treatment has on AR occupancy using ChIP-Seq
analysis. Sequencing results of biological duplicates of non-
treated (NT), 10 nMDHT treated (DHT), and 10 nMDHT
and 10MARE-1 treated (DHT+ARE-1) showed∼30mil-
lion reads mapping for all samples (Supplementary Figure
S3B). Sequencing reads were aligned to hg19 and select AR
target genes are shown (Figure 2A and B).Motif analysis by
MEME discovered the forkhead-binding motif in all sam-
ples, and the complete ARE was discovered in the DHT
and DHT + ARE-1 samples (Supplementary Figure S3C).
Differential binding of DHT/NT and DHT/(DHT+ARE-
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Figure 1. (A) Structure of Py-Im polyamide ARE-1. (B) Nuclear localization of ARE-1-FITC in LNCaP-95 cells after 16-h treatment. (C) Cell viability
as determined by CellTiterGlo assay after 72-h treatment. IC50 is indicated in parentheses. (D) Relative expression of KLK3 in LNCaP-95 cells after the
indicated treatments. Cells were co-treated withARE-1, enzalutamide, or pyrvinium pamoate andDHT at the indicated concentrations andRNAharvested
at 24 h. (E) Schedule of LNCaP-95 xenograft experiment. Animals were engrafted, allowed to grow tumors, castrated, allowed to recover for 7–10 days
and then treated with ARE-1 or vehicle at indicated times. (F) Tumor volumes of LNCaP-95 xenografts in castrated mice treated with vehicle or 2.5 mg/kg
ARE-1 as shown in E. N = 11 for both groups; * P < 0.05, ** P < 0.01, **** P < 0.0001.
1) was calculated using PePr. Analysis revealed 16,015
peaks increased in DHT over non-treated (DHT/NT) and
6343 differentially changedDHT/(DHT+ARE-1) peaks, of
which 4921 overlapped with DHT inducible peaks (Fig-
ure 2C). Correlation of peak location to genomic regions,
conducted by ChIPseeker, showed no difference between
the DHT/NT, DHT/(DHT+ARE-1), and overlap peaks,
suggesting that ARE-1 does not have a regional binding
preference (Figure 2D). Motif analysis of peaks unique to
DHT/NT revealed the canonical ARE where the first half-
site is 5′-RGNACA-3′. In this motif, the first position is se-
lective for A or G (R) and the third position is degenerate
for any base (N) (Figure 2E). Motif analysis of the overlap-
ping peaks between DHT/NT and DHT/(DHT+ARE-1)
also revealed a complete ARE, however the first half-site
has the sequence 5′-RGWACA-3′, where the third position
shows selectivity for A or T (Figure 2E); additional motifs
can be found in Supplementary Figure S4A. Comparison of
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/47/8/3828/5369940 by C
alifornia Institute of Technology user on 01 M
ay 2019
3832 Nucleic Acids Research, 2019, Vol. 47, No. 8
A
C D E
B
Figure 2. ChIP-seq analysis of the KLK3 promoter ARE I (A) and PMEPA1 (B). (C) Overlap of peaks differentially changed in DHT relative to NT, and
peaks changed in DHT relative to DHT and ARE-1. (D) Identified peaks were annotated by genomic region by ChIPseeker. (E) Top ARE motif found by
MEME in the indicated peak sets.
the letter probability matrix between the DHT/NT unique
peaks and the overlapping peaks show more A character
in the first position and reduced C and G character in the
third position in the overlappingmotif (Supplementary Fig-
ure S4B).
Of the possible permutations of the first ARE half-site,
ARE-1 is expected to have the strongest binding to the se-
quences 5′-AGWACA-3′. Based on Py-Im polyamide pair-
ing rules,ARE-1 is expected to have lower binding to the se-
quences 5′-GGWACA-3′ and 5′-AGGACA-3′, which con-
tain single base mismatches, and to have little binding to the
sequence 5′-GGGACA-3′, which contains two mismatches
(Figure 3A) (17–20). DNA thermal stability experiments
confirmed this trend and showed that ARE-1 stabilized
match sequences by ∼9◦C; single mismatches reduced ther-
mal stability by∼2–4◦C.ARE-1 showed no significant ther-
mal stabilization to a double mismatch sequence (Figure
3B).
The ARE half-site sequence 5′-RGNACA-3′ can be split
into four sequences: 5′-AGWACA-3′, 5′-GGWACA-3′, 5′-
AGSACA-3′ and 5′-GGSACA-3′, where S represents G
or C. Density analysis of these four motifs revealed 5′-
AGWACA-3′ to be significantly enriched around the peak
center of DHT/NT and DHT/(DHT+ARE-1) overlap
peaks compared to the other possible motifs. A lesser effect
was found for the DHT/NT unique peaks (Figure 3C–D).
To confirm that the enrichment for 5′-AGWACA-3′ was
only present in regions where AR peaks are affected by
ARE-1, we examined common peaks between DHT/NT
and (DHT+ARE-1)/NT samples (Figure 4A). Of the 7998
overlapping peaks, 2668 peaks had an absolute change of
<1.5-fold. Motif density analysis in these unchanged re-
gions showed no enrichment of 5′-AGWACA-3′ (Figure
4B). Comparatively, 5′-AGWACA-3′ was significantly en-
riched in 2129 peaks showing >2-fold change between
DHT/NT and (DHT+ARE-1)/NT.
DISCUSSION
Py-Im polyamides have been shown to inhibit the signaling
of oncogenic transcription factors and reduce their bind-
ing at select loci in ChIP experiments (12,39,40). Genomic
binding of Py-Im polyamides linked to DNA alkylators
have also been examined (41,42). In this study, we elucidate
the genome-wide effects of polyamide treatment on the AR
on chromatin. Py-Im polyamide ARE-1 is a cell permeable
molecule that exerts anti-proliferative effects toward several
prostate cancer models, including the castration and enza-
lutamide resistant models LREX’ and now LNCaP-95.
In this present study, we find that ARE-1 localizes to
LNCaP-95 nucleus within 16 h of dosing, and is able to
repress ligand-induced gene expression after 24 h of co-
treatment with DHT. In this time frame, our ChIP-Seq re-
sults showARE-1 is able to repress∼30% ofDHT inducible
peaks. Motif analysis of these AR peaks repressed by ARE-
1, which is selective for the sequence 5′-WGWWCW-3′, in-
dicate that these loci are enriched for canonical AREs with
5′-RGWACA-3′ as the first half-site compared to the com-
mon 5′-RGNACA-3′ half-site. Thus, the differential effects
on AR-DNA binding events in vivo reflects the DNA target
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Figure 3. (A) Illustration of match and mismatchARE-1 binding sites. Mismatches are shown in red and boxed. (B) Melting temperature analysis of match
and mismatch sequences shown in A. C + D) Motif density analysis of possible ARE half sites in peaks unique to DHT/NT (C) and overlapping between
DHT/NT and DHT/DHT + ARE-1 (D).
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Figure 4. (A) Venn diagram showing the overlap of peaks differentially changed in DHT as compared to NT with peaks changed by DHT and ARE-1
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sequence binding preference ofARE-1 in vitro. These exper-
iments provide evidence of the in vivo sequence selectivity of
ARE-1, and provide a snapshot of how ARE-1 modulates
the AR cistrome.
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